Preference for the EIA – conjoint results. by Mehdi Mourali (10170245)

“…A randomized conjoint experiment and a follow-up choice experiment revealed that support for the EIAs decreased sharply as their accuracy gap grew, although impact parity was prioritized more when ETAs produced large outcome discrepancies. …”

Signal strength of reports of finasteride administration at the preferred term level in the FAERS database. by Xiaoling Zhong (181270)

Subjects:

Preference for the EIA vs. ETA across scenarios. by Mehdi Mourali (10170245)

“…A randomized conjoint experiment and a follow-up choice experiment revealed that support for the EIAs decreased sharply as their accuracy gap grew, although impact parity was prioritized more when ETAs produced large outcome discrepancies. …”

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2 - by Rosanna Mary Rooney (17595801)

“…Two independent reviewers conducted eligibility decisions and data extraction. Findings has been reported in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.…”

Characteristics of adolescents with T2D cases reporting ADRs to metformin in FAERS. by Mengsi Peng (12882734)

Subjects:

DHE reports decreased cholesterol uptake by ∆<i>mceG</i> Mtb. by Yue Chen (73753)

S8 File - by Martha R. Smith (20410184)

Subjects:

Study populations of included studies. by Martha R. Smith (20410184)

Subjects:

Future research directions. by Martha R. Smith (20410184)

Subjects:

PRISMA flow diagram. by Martha R. Smith (20410184)

Subjects:

S9 File - by Martha R. Smith (20410184)

Subjects:

S7 File - by Martha R. Smith (20410184)

Subjects: